Linagliptin

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Prediabetes was less likely to progress to type 2 diabetes among adults who took a combination of linagliptin and metformin vs. metformin alone; the combination group was also more likely to achieve normal glucose levels, according to findings published in Metabolism.

Adults with early type 2 diabetes and elevated cardiovascular risk who were assigned the DPP-IV inhibitor linagliptin were no more likely to experience a CV event during 6 years of follow-up than similar adults assigned the sulfonylurea glimepiride, according to study data presented at the European Association for the Study of Diabetes annual meeting.

Adults with type 2 diabetes who are treated with DPP-IV inhibitors are more likely to develop pancreatitis and pancreatic cancer compared with those treated with other medications, according to findings published in Diabetes Care.

SAN FRANCISCO — A head-to-head comparison of the sulfonylurea glimepiride against the DPP-IV inhibitor linagliptin in a cohort of more than 6,000 adults with type 2 diabetes demonstrated no between-group differences for incidence of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death during a median of 6 years, according to data from the CAROLINA trial presented at the American Diabetes Association Scientific Sessions.

Top-line results from the CAROLINA study released Thursday demonstrated that the DPP-IV inhibitor linagliptin was noninferior vs. glimepiride for time to first major adverse cardiovascular event in adults with type 2 diabetes at high CV risk, according to a press release from Boehringer Ingelheim and Eli Lilly.